NCp7: targeting a multitasking protein for next-generation anti-HIV drug development part 1: covalent inhibitors

Drug Discov Today. 2018 Feb;23(2):260-271. doi: 10.1016/j.drudis.2017.10.017. Epub 2017 Oct 28.

Abstract

The major internal component of the HIV virion core is the nucleocapsid protein 7 (NCp7), a small, highly basic protein that is essential for multiple stages of the viral replicative cycle, and whose structure is preserved in all viral strains, including clinical isolates from therapy-experienced patients. This key protein is recognised as a potential target for an effective next-generation antiretroviral therapy, because it could offer the possibility to develop broad-spectrum agents that are less prone to select for resistant strains. Here, we provide a comprehensive overview of the covalent NCp7 inhibitors that have emerged over the past 25 years of drug discovery campaigns, emphasising, where possible, their structure-activity relationships (SARs) and pharmacophoric features.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use*
  • Drug Discovery / methods
  • Humans
  • Nucleocapsid Proteins / antagonists & inhibitors
  • Structure-Activity Relationship
  • Viral Proteins / antagonists & inhibitors
  • gag Gene Products, Human Immunodeficiency Virus / antagonists & inhibitors*

Substances

  • Anti-HIV Agents
  • NCP7 protein, Human immunodeficiency virus 1
  • Nucleocapsid Proteins
  • Viral Proteins
  • gag Gene Products, Human Immunodeficiency Virus